Eliem Therapeutics GAAP EPS of -$0.13

Seeking AlphaNov 14 12:45 ET

Climb Bio Inc. Shifts Focus to Immune-Mediated Diseases

TipRanksNov 13 23:40 ET

Express News | Climb Bio Inc Files for Mixed Shelf of up to $200 Mln - SEC Filing

ReutersNov 12 16:52 ET

Climb Bio 3Q Loss/Shr 13c >CLYM

Dow JonesNov 12 16:49 ET

Climb Bio Reports Q3 EPS (13c) Vs (15c) Last Year

TipRanksNov 12 16:47 ET

Climb Bio | 8-K: Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

SECNov 12 16:42 ET